A novel simultaneous high performance liquid chromatography-PDA method for the determination of Tenofovir AF, Darunavir, Emtricitabine and Cobicistat in bulk and its application to marketed formulation

A novel simultaneous high performance liquid chromatography-PDA method for the determination of Tenofovir AF, Darunavir, Emtricitabine and Cobicistat in bulk and its application to marketed formulation Challamalla Pavani E. Susithra Abstract Background

The present research article involves the simultaneous determination of Tenofovir alafenamide, Darunavir, Emtricitabine and Cobicistat in bulk as well as in tablet dosage form using high performance liquid chromatography.
Result

The separation was performed using DIKMA Spursil, C 18 , ODS, (4.6 × 150 mm × 5 µm) analytical column using the mobile phase acetonitrile and 0.1% Orthophosphoric acid in the volume ratio of 70:30 at pH 3. The eluents were detected using PDA detector at 254.0 nm. After optimization subsequent validation study of different parameters was performed by utilizing the optimised condition as per the ICH guidelines. Under this optimised conditions Tenofovir alafenamide, Darunavir, Emtricitabine and Cobicistat were eluted at 2.287 min, 2.507 min, 4.062 min, 6.011 min respectively. Percentage assay was found 99.21% for Tenofovir alafenamide, 99.80% for Darunavir, 99.80% for Emtricitabine and 99.84% for Cobicistat. Tenofovir alafenamide was found linear in the range of 2.0–10.0 µg/mL, Darunavir (160.0–800.0 µg/mL), Emtricitabine (40.0–200.0 µg/mL) and for cobicistat (30.0–150.0 µg/mL). The corelation coefficient was found 0.999 for all the APIs. The detection limit was found 0.14 µg/mL for Tenofovir alafenamide, 2.14 µg/mL for Darunavir, 0.6 µg/mL for Emtricitabine and 7.32 µg/mL for cobicistat. In the LOQ study the quantitation limit was found 0.47 µg/mL for Tenofovir alafenamide, 7.12 µg/mL for Darunavir, 2.10 µg/mL, for Emtricitabine and 24.42 µg/mL for cobicistat.
Conclusion

All the studied API’s has been highly resolute utilizing the optimised condition and found extremely suitable for the determination of all of them simultaneously in marketed dosage form as well as in the bulk form.
01 04 2022 12 2022 2 390 1 10.1007/springer_crossmark_policy link.springer.com false 1 November 2021 17 December 2021 4 January 2022 Non applicable. Non applicable. The authors declares that they have no competing interest. https://creativecommons.org/licenses/by/4.0 https://creativecommons.org/licenses/by/4.0 10.1186/s43094-021-00390-5 20220104110759976 https://fjps.springeropen.com/articles/10.1186/s43094-021-00390-5 https://link.springer.com/content/pdf/10.1186/s43094-021-00390-5.pdf https://link.springer.com/content/pdf/10.1186/s43094-021-00390-5.pdf https://link.springer.com/article/10.1186/s43094-021-00390-5/fulltext.html British HIV Association (2016) BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy (2016 interim update). http://www.bhiva.org. Accessed 3 June 2021 Med Today D Baker 15 2 16 2014 Baker D, Pell C, Donovan B (2014) HIV as a chronic disease. Optimizing outcomes. Med Today 15(2):16–26 European AIDS Clinical Society. Guidelines Version 9.0. (2017). http://eacsociety.org/. Accessed 16 June 2021 Pharmacotherapy BM Shah 33 10 1107 2013 10.1002/phar.1237 Shah BM, Schafer JJ, Priano J (2013) Cobicistat: a new boost for the treatment of human immunodefciency virus infection. Pharmacotherapy 33(10):1107–1116 Drugs ED Deeks 78 10 1013 2018 10.1007/s40265-018-0934-2 Deeks ED (2018) Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: a review in HIV-1 infection. Drugs 78(10):1013–1024 Virus Adapt Treat MV Cossu 7 47 2015 10.2147/VAAT.S83680 Cossu MV, Astuti N, Capetti A, Rizzardini G (2015) Impact and diferential clinical utility of cobicistat-boosted darunavir in HIV/AIDS. Virus Adapt Treat 7:47–56 Europian Medicine Agency (2017) An overview of Symtuza. https://www.ema.europa.eu/en/medicines/human/EPAR/symtuza. Accessed 12 June 2021 Res J Chem Environ G Suresh 25 9 79 2021 10.25303/259rjce7988 Suresh G, Manikandan A, Rao SV (2021) A simple reverse phase UPLC validated method for concurrent estimation of Emtricitabine, Darunavir, Tenofovir and Cobicistat in drug substances and drug product. Res J Chem Environ 25(9):79–88 Int J Pharm Sci Res SA Parameswari 12 6 3216 2021 Parameswari SA, Ankinapalli AKR, Tsegaye T, Alagusundaram M (2021) Stability indicating RP-HPLC method development and validation for the simultaneous estimation of darunavir, cobicistat, emtricitabine and tenofovir alafenamide in bulk and pharmaceutical formulation. Int J Pharm Sci Res 12(6):3216–3224 Anal Chem Lett P Mondal 8 1 131 2018 10.1080/22297928.2017.1400921 Mondal P, Mahender K, Padmaja B (2018) A novel UPLC-PDA method for the simultaneous determination of Lamivudine, Zidovudine and Nevirapine in bulk and tablet dosage form. Anal Chem Lett 8(1):131–138